|
|
Vol. 15.23 – 4 October, 2024
|
|
|
|
|
|
|
|
The authors used genomic data from 3,963 cases and 3,509 controls from Ghana, Nigeria, Senegal, South Africa and Uganda to infer ancestry-specific genetic architectures and fine-map disease associations. [Nature Genetics]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Scientists developed the targeted microtubules transformable nanopeptide system. This system was designed to disrupt microtubule structure and function through dual-targeting of prostate-specific membrane antigen and β-tubulin.
[Advanced Materials]
|
|
|
|
|
|
Using isogenic prostate cancer models generated by CRISPR/Cas9-mediated inactivation of CDK12, the authors conducted a chemical library screen of ~1800 FDA-approved drugs. They inhibited cyclin K and CDK13 and evaluated the effects on poly ADP-ribose polymerase inhibitor sensitivity.
[Clinical Cancer Research]
|
|
|
|
|
|
Scientists conducted a Phase II, multi-center, single-arm trial evaluating nivolumab in post-docetaxel metastatic castration-resistant prostate cancer patients. DNA repair defects were assessed using circulating tumor DNA.
[Clinical Cancer Research]
|
|
|
|
|
|
Investigators identified three distinct proteomic subtypes with significant difference in both molecular features and clinical prognosis.
[Proceedings of The National Academy of Sciences of The United States of America]
|
|
|
|
|
|
Researchers described a patient with two treatment-emergent metastatic lesions, one to the brain with neuroendocrine prostate cancer histology and one to the dural membrane of adenocarcinoma histology. [NPJ Precision Oncology]
|
|
|
|
|
|
Prostate cancer stem cells were isolated from various prostate cancer cell lines and clinical tumour tissues using multiple methods for various in vitro and in vivo oncogenic growth analyses.
[British Journal of Cancer]
|
|
|
|
|
|
This was a single-institution, single-arm, non-therapeutic, interventional trial of 166 men with biopsy-confirmed prostate cancer enrolled between 2014–2020.
[Prostate Cancer and Prostatic Diseases]
|
|
|
|
|
|
Patients with prostate cancer (PC) who express PDIA2 high in particular have a bad prognosis in terms of progression-free survival. The upregulation of PDIA2 expression in PC patients was accompanied by higher Gleason scores, advanced tumor staging, lymph node metastasis, and elevated PSA levels. [Scientific Reports]
|
|
|
|
|
|
|
|
|
Scientists summarize the current evidence regarding the biological functions and molecular mechanisms of LINC01116 in the progression of cancer, providing theoretical references for LINC01116-related cancer treatment in the future. [Heliyon]
|
|
|
|
|
|
|
|
A “dangerously biased” combination of social factors and inadequate research is raising Black men’s already-heightened risk of developing prostate cancer, a UK charity has stated
[Forbes]
|
|
|
|
|
|
Curium announced that it has entered into a strategic partnership with PDRadiopharma, Inc, a wholly-owned subsidiary of PeptiDream, for the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T.
[Curium]
|
|
|
|
|
|
pharmaand GmbH and Tolmar, Inc. announced an exclusive agreement for Tolmar to promote Rubraca in the US for the treatment of metastatic castration-resistant prostate cancer. [pharmaand GmbH (PR Newswire)]
|
|
|
|
|
|
|
|
November 6-8, 2024 London, England, United Kongdom
|
|
|
|
|
|
|
|
|
|
|
Wellcome Trust – Cambridge, England, United Kingdom
|
|
|
|
|
|
|
Northwell Health – Manhasset, New York, United States
|
|
|
|
|
|
|
Fred Hutch Cancer Center – Seattle, Washington, United States
|
|
|
|
|
|
|
Vancouver Prostate Centre – Vancouver, British Columbia, Canada
|
|
|
|
|
|
|
Dana-Farber Cancer Institute – Boston, Massachusetts, United States
|
|
|
|
|
|